- Home
- IGI vs NRXS Comparison
IGI vs NRXS Comparison
Compare IGI & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | IGI | NRXS |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.2M | 78.9M |
| IPO Year | 2009 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IGI | NRXS |
|---|---|---|
| Price | $16.06 | $7.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 18.8K | ★ 208.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $142.91 |
| Revenue Next Year | N/A | $120.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $15.70 | $1.33 |
| 52 Week High | $17.09 | $7.97 |
Technical Indicators
Market Signals| Indicator | IGI | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 59.05 |
| Support Level | $15.78 | $2.36 |
| Resistance Level | $16.66 | $7.97 |
| Average True Range (ATR) | 0.22 | 0.69 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 54.12 | 62.69 |
Price Performance
Historical ComparisonAbout IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).